Lineage Cell Therapeutics (LCTX) Net Equity Issued and Repurchased (2011 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Net Equity Issued and Repurchased of -$5.2 million for Q4 2025, up 62.14% year-over-year from -$3.2 million in Q4 2024, and down 200.0% quarter-over-quarter from $5.2 million in Q3 2025.
Lineage Cell Therapeutics (LCTX) Net Equity Issued and Repurchased (2011 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Net Equity Issued and Repurchased history runs 12 years deep, the most recent figure standing at -$5.2 million for Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased rose 62.14% year-over-year to -$5.2 million; the TTM figure through Mar 2026 stood at -$5.3 million (up 37.86% YoY), while the FY2024 annual figure was $68000.0, down 98.94% from the prior year.
- Net Equity Issued and Repurchased for Q4 2025 stood at -$5.2 million, down from $5.2 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $19.9 million in Q1 2021, with the low at -$13.8 million in Q4 2024.
- The 5-year median for Net Equity Issued and Repurchased is $1.8 million (2021), against an average of $2.7 million.
- The sharpest annual moves came in 2024 and 2025: Net Equity Issued and Repurchased tumbled 6845.23% in 2024, then surged 62.14% in 2025.
- Lineage Cell Therapeutics' Net Equity Issued and Repurchased stood at $124000.0 in 2021, then climbed by 19.35% to $148000.0 in 2022, then sank by 234.46% to -$199000.0 in 2023, then sank by 6845.23% to -$13.8 million in 2024, then soared by 62.14% to -$5.2 million in 2025.
- Business Quant data shows LCTX's Net Equity Issued and Repurchased at -$5.2 million in Q4 2025, $5.2 million in Q3 2025, and -$5.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | 4.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.47 Mn |
| Jun 30, 2026 | 4.47 Mn |
| Dec 31, 2025 | -5.23 Mn |
| Dec 31, 2025 | -5.23 Mn |
| Sep 30, 2025 | 5.23 Mn |
| Sep 30, 2025 | 5.23 Mn |
| Jun 30, 2025 | -5.30 Mn |
| Jun 30, 2025 | -5.30 Mn |
| Mar 31, 2025 | 5.30 Mn |
| Mar 31, 2025 | 5.30 Mn |
| Dec 31, 2024 | -13.82 Mn |
| Dec 31, 2024 | -13.82 Mn |
| Mar 31, 2024 | 13.89 Mn |
| Mar 31, 2024 | 13.89 Mn |
| Dec 31, 2023 | -199,000.00 |
| Dec 31, 2023 | -199,000.00 |
| Sep 30, 2023 | 836,000.00 |
| Sep 30, 2023 | 836,000.00 |
| Jun 30, 2023 | 5.79 Mn |
| Jun 30, 2023 | 5.79 Mn |